Vadastuximab disitamab vedotin antibody-drug compound representing a crucial advancement in the treatment of acute myeloid leukemia (AML). This groundbreaking therapy precisely targets CD33, a protein https://mediajx.com/story27851060/vadastuximab-a-deep-dive-into-cd33-targeted-therapy